Experienced in Floating-Harbor Syndrome

Didier Hannequin

Rouen, FR 
Experienced in Floating-Harbor Syndrome
Rouen, FR 
OverviewLocationsClinical Research

Overview

Didier Hannequin practices in Rouen, France. Mr. Hannequin is rated as an Experienced expert by MediFind in the treatment of Floating-Harbor Syndrome. His top areas of expertise are Primary Familial Brain Calcification, Dementia, Alzheimer's Disease, and Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease).

His clinical research consists of co-authoring 121 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Floating-Harbor Syndrome.

Gender
Male

Locations

Rouen, 76000, France
Other Locations
CHU Bordeaux
Bordeaux, France
Lille, 59000, France
Paris, France
Boulevard De La Chantourne, La Tronche, 38700, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Characterization of Clinical, Biological, Morphological and Pharmacological Factors Influencing Occurrence of Dementia or Cognitive Disorders After Stroke
Characterization of Clinical, Biological, Morphological and Pharmacological Factors Influencing Occurrence of Dementia or Cognitive Disorders After Stroke
Enrollment Status: Completed
Publish Date: December 16, 2025
A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease
A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: November 12, 2025
Intervention Type: Drug
Study Drugs: Gantenerumab, Solanezumab
Study Phase: Phase 2/Phase 3
Clinical and Genetic Analysis of Autosomal Recessive Forms of Cerebellar Ataxias and Spastic Paraplegias
Clinical and Genetic Analysis of Autosomal Recessive Forms of Cerebellar Ataxias and Spastic Paraplegias
Enrollment Status: Completed
Publish Date: February 04, 2025
Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
Enrollment Status: Completed
Publish Date: January 23, 2025
Intervention Type: Other
Multicentric, Randomized, Double-blind Versus Placebo Study Evaluating the Efficacy of Treatment With Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of Multiple Sclerosis (MS) After a Clinically Isolated Syndrome (CIS). Comparison of Conversion Rates After 2 Years.
Multicentric, Randomized, Double-blind Versus Placebo Study Evaluating the Efficacy of Treatment With Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of Multiple Sclerosis (MS) After a Clinically Isolated Syndrome (CIS). Comparison of Conversion Rates After 2 Years.
Enrollment Status: Completed
Publish Date: January 12, 2024
Intervention Type: Biological, Drug, Other
Study Drugs: Vitamin D, Lumbar Puncture, Blood Sampling, Urine Samples
Study Phase: Phase 3
Impact of Controlling Vascular Risk Factors on the Progression of Alzheimer's Disease
Impact of Controlling Vascular Risk Factors on the Progression of Alzheimer's Disease
Enrollment Status: Completed
Publish Date: May 24, 2022
Intervention Type: Other
Study Phase: Not Applicable
Longitudinal Study of Brain Amyloid imaGing in MEMENTO
Longitudinal Study of Brain Amyloid imaGing in MEMENTO
Enrollment Status: Completed
Publish Date: February 03, 2022
Intervention Type: Drug
Study Drugs: Flutemetamol, Florbetapir
Study Phase: Phase 3
View 6 Less Clinical Trials

119 Total Publications

Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU): Trial Satisfaction and Attitudes towards Future Clinical Trials.
Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU): Trial Satisfaction and Attitudes towards Future Clinical Trials.
Journal: The journal of prevention of Alzheimer's disease..
Published: May 06, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Hannequin's expertise for a condition
ConditionClose
    View All 26 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile